SunTrust Banks, Inc. reaffirmed their buy rating on shares of Stryker Corporation (NYSE:SYK) in a report published on Friday morning. They currently have a $161.00 price target on the medical technology company’s stock.
A number of other analysts have also recently issued reports on SYK. Zacks Investment Research cut Stryker Corporation from a buy rating to a hold rating in a research report on Thursday, July 27th. Royal Bank Of Canada boosted their price objective on Stryker Corporation from $140.00 to $155.00 and gave the company an outperform rating in a research report on Friday, July 28th. Oppenheimer Holdings, Inc. set a $148.00 price objective on Stryker Corporation and gave the company a hold rating in a research report on Friday, July 28th. Stifel Nicolaus boosted their price objective on Stryker Corporation from $151.00 to $158.00 and gave the company a buy rating in a research report on Friday, July 28th. Finally, Cowen and Company restated a buy rating and set a $160.00 price objective (up from $150.00) on shares of Stryker Corporation in a research report on Sunday, July 30th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and fourteen have given a buy rating to the stock. Stryker Corporation has a consensus rating of Hold and an average target price of $152.10.
Shares of Stryker Corporation (NYSE:SYK) traded down $1.07 during midday trading on Friday, reaching $155.40. The company’s stock had a trading volume of 936,961 shares, compared to its average volume of 1,190,000. The company has a current ratio of 2.37, a quick ratio of 1.61 and a debt-to-equity ratio of 0.63. The company has a market cap of $57,760.00, a P/E ratio of 24.72, a P/E/G ratio of 2.46 and a beta of 0.79. Stryker Corporation has a 52 week low of $108.29 and a 52 week high of $160.62.
Stryker Corporation (NYSE:SYK) last released its quarterly earnings data on Thursday, October 26th. The medical technology company reported $1.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.50 by $0.02. The business had revenue of $3.01 billion for the quarter, compared to analysts’ expectations of $2.97 billion. Stryker Corporation had a return on equity of 24.11% and a net margin of 14.67%. Stryker Corporation’s quarterly revenue was up 6.1% on a year-over-year basis. During the same period in the previous year, the business posted $1.39 earnings per share. sell-side analysts expect that Stryker Corporation will post 6.47 earnings per share for the current year.
WARNING: “Stryker Corporation’s (SYK) Buy Rating Reaffirmed at SunTrust Banks, Inc.” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another domain, it was stolen and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.dispatchtribunal.com/2017/11/18/stryker-corporations-syk-buy-rating-reaffirmed-at-suntrust-banks-inc.html.
In other Stryker Corporation news, insider Lonny J. Carpenter sold 5,000 shares of the business’s stock in a transaction on Friday, November 3rd. The stock was sold at an average price of $155.34, for a total value of $776,700.00. Following the transaction, the insider now owns 83,207 shares of the company’s stock, valued at $12,925,375.38. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 7.40% of the stock is currently owned by insiders.
Several hedge funds have recently added to or reduced their stakes in the company. Cetera Investment Advisers raised its position in shares of Stryker Corporation by 9.3% during the third quarter. Cetera Investment Advisers now owns 4,883 shares of the medical technology company’s stock worth $689,000 after acquiring an additional 415 shares during the last quarter. IFM Investors Pty Ltd bought a new stake in shares of Stryker Corporation during the third quarter worth $1,326,000. Marco Investment Management LLC raised its position in shares of Stryker Corporation by 10.4% during the third quarter. Marco Investment Management LLC now owns 70,875 shares of the medical technology company’s stock worth $10,066,000 after acquiring an additional 6,685 shares during the last quarter. Baker Chad R raised its position in shares of Stryker Corporation by 3.9% during the third quarter. Baker Chad R now owns 18,070 shares of the medical technology company’s stock worth $2,567,000 after acquiring an additional 670 shares during the last quarter. Finally, Guardian Capital LP raised its position in shares of Stryker Corporation by 4.1% during the third quarter. Guardian Capital LP now owns 124,492 shares of the medical technology company’s stock worth $17,680,000 after acquiring an additional 4,849 shares during the last quarter. Institutional investors own 74.15% of the company’s stock.
About Stryker Corporation
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.